HUE040524T2 - Mellrák kezelése - Google Patents

Mellrák kezelése

Info

Publication number: HUE040524T2
Authority: HU; Hungary
Prior art keywords: treatment; breast cancer; breast; cancer
Prior art date: 2011-07-29

Application number

HUE12846720A

Other languages

English (en)

Inventor

Andrew A Protter

Jennifer Richer

Dawn Cochrane

Original Assignee

Medivation Prostate Therapeutics Llc

Univ Colorado Regents

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-29

Filing date

2012-07-27

Publication date

2019-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE040524(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-27 Application filed by Medivation Prostate Therapeutics Llc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Llc

2019-03-28 Publication of HUE040524T2 publication Critical patent/HUE040524T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUE12846720A 2011-07-29 2012-07-27 Mellrák kezelése HUE040524T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161513361P	2011-07-29	2011-07-29

Publications (1)

Publication Number	Publication Date
HUE040524T2 true HUE040524T2 (hu)	2019-03-28

Family

ID=48192564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE12846720A HUE040524T2 (hu)	2011-07-29	2012-07-27	Mellrák kezelése

Country Status (18)

Country	Link
US (4)	US9517229B2 (hu)
EP (4)	EP3430907A1 (hu)
JP (2)	JP6158180B2 (hu)
KR (1)	KR101923250B1 (hu)
CN (1)	CN103997894B (hu)
BR (1)	BR112014002200A2 (hu)
CA (1)	CA2843417C (hu)
CY (1)	CY1121038T1 (hu)
DK (1)	DK2739153T3 (hu)
EA (1)	EA028452B1 (hu)
ES (1)	ES2696074T3 (hu)
HU (1)	HUE040524T2 (hu)
MX (1)	MX359664B (hu)
PH (1)	PH12014500248B1 (hu)
PL (1)	PL2739153T3 (hu)
PT (1)	PT2739153T (hu)
SI (1)	SI2739153T1 (hu)
WO (1)	WO2013066440A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE040524T2 (hu) *	2011-07-29	2019-03-28	Medivation Prostate Therapeutics Llc	Mellrák kezelése
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
MX371020B (es)	2012-09-26	2020-01-13	Aragon Pharmaceuticals Inc	Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
JOP20200097A1 (ar) *	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
WO2014172431A1 (en) *	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR20160070188A (ko) *	2013-11-07	2016-06-17	데시페라 파마슈티칼스, 엘엘씨.	암치료에 유용한 tie2 키나아제의 억제 방법
JP6945587B2 (ja) *	2013-11-07	2021-10-06	デシフェラファーマシューティカルズ，エルエルシー	ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) *	2014-05-28	2019-10-02	Eisai R&D Management Co., Ltd.	Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
RU2017120330A (ru)	2014-12-12	2019-01-14	Медивэйшн Простейт Терапьютикс, Ллс	Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
US9895313B2 (en)	2015-03-03	2018-02-20	Cureport, Inc.	Combination liposomal pharmaceutical formulations
EP3265063A4 (en)	2015-03-03	2018-11-07	Cureport, Inc.	Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) *	2015-05-14	2018-04-27	南京海纳医药科技股份有限公司	一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) *	2016-01-29	2018-05-08	Wayne State University	Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
MY198676A (en)	2017-06-22	2023-09-15	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
SG11202003402QA (en)	2017-10-16	2020-05-28	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) *	2017-12-19	2018-05-04	刘秀云	硫代咪唑二酮类雄激素受体拮抗剂及其用途
JP2021512105A (ja)	2018-01-31	2021-05-13	デシフェラ・ファーマシューティカルズ，エルエルシー	消化管間質腫瘍の治療のための併用療法
KR102867888B1 (ko)	2018-01-31	2025-10-13	데시페라 파마슈티칼스, 엘엘씨	비만 세포증의 치료를 위한 병용 요법
EP3886853A4 (en) *	2018-11-30	2022-07-06	Nuvation Bio Inc.	DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF
EP3886854A4 (en)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
BR112022002609A2 (pt)	2019-08-12	2022-08-09	Deciphera Pharmaceuticals Llc	Métodos de tratamento de tumores estromais gastrointestinais
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
MX2022008097A (es)	2019-12-30	2022-09-19	Deciphera Pharmaceuticals Llc	Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
KR20220123057A (ko)	2019-12-30	2022-09-05	데시페라 파마슈티칼스, 엘엘씨.	비정질 키나아제 억제제 제형 및 이의 사용 방법
CN116322639A (zh) *	2020-08-03	2023-06-23	昂科赛特公司	肿瘤分类和反应性预测
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4559157A (en)	1983-04-21	1985-12-17	Creative Products Resource Associates, Ltd.	Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr)	1983-08-30	1985-04-24	Oreal	Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en)	1987-06-23	1989-04-11	Neutrogena Corporation	Skin protective composition
US4992478A (en)	1988-04-04	1991-02-12	Warner-Lambert Company	Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en)	1988-09-12	1990-07-03	University Of New York	Treatment of damaged bone marrow and dosage units therefor
SI1893196T2 (sl)	2005-05-13	2015-10-30	The Regents Of The University Of California	Diarilhidantoinska spojina
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CA2630974A1 (en)	2005-11-23	2007-05-31	University Of Utah Research Foundation	Methods and compositions involving intrinsic genes
DK2004181T6 (da) *	2006-03-27	2023-08-21	Univ California	Androgen receptormodulator til behandling af prostatacancer og androgen receptor-associerede sygdomme
JP5350217B2 (ja)	2006-03-29	2013-11-27	ザリージェンツオブザユニバーシティオブカリフォルニア	ジアリールチオヒダントイン化合物
EP2620432A3 (en)	2007-10-26	2013-12-18	The Regents Of the University of California	Diarylhydantoin compounds
US8450290B2 (en)	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) *	2008-03-14	2011-06-02	The Regents Of The University Of California	Multi-gene classifiers and prognostic indicators for cancers
AU2009262894B2 (en)	2008-05-30	2014-01-30	British Columbia Cancer Agency Branch	Gene expression profiles to predict breast cancer outcomes
EP2400847B1 (en)	2009-02-24	2014-12-17	Medivation Prostate Therapeutics, Inc.	Specific diarylthiohydantoin compounds
WO2010118354A1 (en)	2009-04-09	2010-10-14	Medivation Prostate Therapeutics, Inc.	Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
US8507195B2 (en) *	2009-08-20	2013-08-13	The Regents Of The University Of Colorado	MiRNAs dysregulated in triple-negative breast cancer
WO2011044327A1 (en)	2009-10-07	2011-04-14	Medivation Prostate Therapeutics, Inc.	Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
CA2830240A1 (en)	2011-03-15	2012-09-20	The University Of North Carolina At Chapell Hill	Methods of treating breast cancer with anthracycline therapy
HUE040524T2 (hu) *	2011-07-29	2019-03-28	Medivation Prostate Therapeutics Llc	Mellrák kezelése
CA2857505A1 (en)	2011-11-30	2013-06-06	The University Of North Carolina At Chapel Hill	Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en)	2012-08-23	2014-02-27	The Regents Of The University Of Colorado, A Body Corporate	Method for determining breast cancer treatment
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
US20140154681A1 (en)	2012-11-12	2014-06-05	Nanostring Technologies, Inc.	Methods to Predict Breast Cancer Outcome
US10679730B2 (en)	2013-05-28	2020-06-09	The University Of Chicago	Prognostic and predictive breast cancer signature
RU2017120330A (ru)	2014-12-12	2019-01-14	Медивэйшн Простейт Терапьютикс, Ллс	Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы

2012
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en not_active Ceased
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active Active
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/en active
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 PH PH1/2014/500248A patent/PH12014500248B1/en unknown
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20210069154A1 (en)	2021-03-11
HK1198867A1 (en)	2015-06-19
JP2017141269A (ja)	2017-08-17
PH12014500248A1 (en)	2014-03-17
CN103997894B (zh)	2016-08-24
WO2013066440A9 (en)	2013-07-18
MX359664B (es)	2018-10-05
EP2739153B1 (en)	2018-08-22
SI2739153T1 (sl)	2018-12-31
MX2014001218A (es)	2014-08-22
EP2739153A4 (en)	2015-03-11
JP6158180B2 (ja)	2017-07-05
US20190262315A1 (en)	2019-08-29
CY1121038T1 (el)	2019-12-11
PL2739153T3 (pl)	2019-04-30
US20170087132A1 (en)	2017-03-30
US10111861B2 (en)	2018-10-30
ES2696074T3 (es)	2019-01-14
EP3791724A1 (en)	2021-03-17
EP2739153A1 (en)	2014-06-11
US20140296312A1 (en)	2014-10-02
CA2843417C (en)	2018-08-21
HK1201413A1 (en)	2015-09-04
EA201400178A1 (ru)	2014-11-28
BR112014002200A2 (pt)	2017-03-07
PT2739153T (pt)	2018-11-28
WO2013066440A1 (en)	2013-05-10
EP3610731A1 (en)	2020-02-19
US9517229B2 (en)	2016-12-13
KR101923250B1 (ko)	2018-11-28
CN103997894A (zh)	2014-08-20
KR20140107174A (ko)	2014-09-04
PH12014500248B1 (en)	2018-08-31
JP2014524934A (ja)	2014-09-25
DK2739153T3 (en)	2018-12-03
EP3430907A1 (en)	2019-01-23
EA028452B1 (ru)	2017-11-30
CA2843417A1 (en)	2013-05-10

Publication	Publication Date	Title
IL289300A (en)	2022-02-01	Combination therapy for treating cancer
HUE040524T2 (hu)	2019-03-28	Mellrák kezelése
HUE047198T2 (hu)	2020-04-28	Fitokannabinoidok emlõrák kezelésére
HUE048876T2 (hu)	2020-08-28	Rákos megbetegedések kezelése
HUE046790T2 (hu)	2020-03-30	A rák kezelésének módszerei
DK2717941T3 (da)	2020-07-13	Behandling af cancer
BR112014007603A2 (pt)	2017-06-13	métodos de tratamento do câncer
DK2785349T3 (da)	2020-01-02	Kombinationsbehandling af cancer
PL2552438T3 (pl)	2016-12-30	Sposoby leczenia raka wątrobowokomórkowego
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
IL228538A0 (en)	2013-12-31	Methods for increasing efficacy of folr1 cancer therapy
EP2920308A4 (en)	2016-06-29	CANCER TREATMENT
IL224370B (en)	2018-04-30	Combination treatment for prostate carcinoma
BR112014012880A2 (pt)	2017-06-13	tratamento imunogênico do câncer
EP2751267A4 (en)	2015-01-07	METHOD FOR THE TREATMENT OF BREAST CANCER
HRP20190046T1 (hr)	2019-05-03	Kombinirana terapija za liječenje raka
IL226246A0 (en)	2013-07-31	Methods of treating cancer
IL228430A0 (en)	2013-12-31	Cancer treatment
EP2817011A4 (en)	2015-08-19	CANCER TREATMENT
EP2903644A4 (en)	2016-03-09	TREATMENT OF CANCER
GB201217892D0 (en)	2012-11-21	Treatment of cancer
GB201217890D0 (en)	2012-11-21	Treatment of cancer
GB201121783D0 (en)	2012-02-01	Treatment of cancer
GB201121791D0 (en)	2012-02-01	Combination treatment of cancer
GB201208296D0 (en)	2012-06-20	Treatment of cancer